PT-141

PT-141, known by its International Nonproprietary Name bremelanotide and the brand name Vyleesi, is a synthetic cyclic peptide and an analogue of the naturally occurring hormone alpha-melanocyte-stimulating hormone (alpha-MSH) ^[1][2]. It acts as an agonist at melanocortin receptors, principally the melanocortin type 4 receptor (MC4R) and, to a lesser extent, the type 3 receptor (MC3R), which are expressed largely in the central nervous system and are thought to be important for sexual function ^[1][2]. It was developed by Palatin Technologies from the melanocortin agonist lineage and was first investigated as an intranasal spray for erectile dysfunction and female sexual dysfunction before being reformulated as a subcutaneous injection ^[5][7].

The defining feature of PT-141 is that it works centrally, acting on brain pathways that govern sexual desire and arousal, rather than on the vascular system like the PDE5 inhibitors used for erectile dysfunction ^[1][2]. Early studies showed that systemic PT-141 produced penile erections in animals and in men, and separate work found it improved subjective sexual desire and arousal in premenopausal women ^[1][5]. Development ultimately focused on female hypoactive sexual desire disorder (HSDD), a condition of persistently low sexual desire causing marked distress, and on this indication bremelanotide completed a full phase 1 through phase 3 clinical program ^[2][6].

In June 2019 the United States Food and Drug Administration approved bremelanotide (Vyleesi) for the treatment of acquired, generalized HSDD in premenopausal women, delivered as a self-administered, on-demand subcutaneous injection of 1.75 mg taken before anticipated sexual activity ^[2][3]. It is one of only two drugs approved for HSDD, the other being flibanserin ^[2]. Outside this approved use, PT-141 is also sold as a research peptide and used off-label or experimentally for male and female sexual dysfunction; in that unregulated market its quality and purity are not guaranteed ^[3][7].

PT-141 (bremelanotide) commonly causes nausea, which can be significant, along with flushing and headache, and it produces transient increases in blood pressure and decreases in heart rate, so it is not recommended in uncontrolled hypertension or known cardiovascular disease. Repeated use can cause focal darkening of the skin, gums, or face, and injection-site reactions are common. Its cardiovascular effects warrant caution in at-risk individuals, and it should not be dosed frequently.

Bremelanotide (PT-141) undergoes Phase 1 and Phase 2 metabolism. In clinical trials, bremelanotide lowered plasma concentrations of indomethacin and naltrexone; the mechanism appears pharmacokinetic but was not fully characterized ^[6]. Small and transient statistically significant increases in blood pressure occurred during ambulatory monitoring; the clinical relevance of this pharmacodynamic effect was deemed modest. Bremelanotide's most common adverse event is nausea, reported in 40% of treated subjects versus 1.3% of placebo, suggesting direct pharmacodynamic activity rather than an interaction mechanism. Not documented; the specific mechanism of the indomethacin and naltrexone concentration reductions was not elucidated in published trials, and most other drug-drug interactions were not clinically significant.

Checking a whole stack? Run it through interactions + stacks.

PT-141, or bremelanotide, emerged from research on Melanotan II, a cyclic melanocortin agonist studied at the University of Arizona; investigators observed that the compound produced unexpected sexual arousal effects, prompting a focused development program. Palatin Technologies advanced a related melanocortin peptide specifically for sexual dysfunction, tracing its central action to melanocortin receptors in the brain rather than the vasculature.

Early animal work showed that systemic PT-141 activated hypothalamic neurons linked to erectile tissue, distinguishing it mechanistically from vascular erectile-dysfunction drugs. After two large phase 3 trials known collectively as RECONNECT demonstrated significant improvements in desire and reductions in desire-related distress, the FDA approved bremelanotide as Vyleesi in June 2019 for hypoactive sexual desire disorder in premenopausal women.

PT-141 is prized as a genuinely novel approach to low sexual desire, one of the few desire-boosting agents supported by large randomized controlled trials rather than anecdote. Its brain-based mechanism sets it apart from erectile-focused drugs and gives it appeal across both sexes, since it targets the central drive for desire rather than a mechanical arousal step. The FDA approval of Vyleesi lends it a level of regulatory validation uncommon among research peptides. Discussion is candid about its trade-offs; clinical effect sizes are statistically robust but modest, and characteristic side effects such as nausea, flushing, and headache are common because the same melanocortin activity extends beyond the receptors governing sexual response. This honest profile of real efficacy alongside tolerability considerations shapes its reputation.